YAG
NRSN icon

Yorkville Advisors Global’s NeuroSense Therapeutics NRSN Stock Holding History

Yorkville Advisors Global’s Portfolio NRSN Stock Details NRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$56.2K Hold
3,900
– – 0.07% 34
2026
Q1 		$58.9K Sell
3,900
-1,100
-22% -$19.6K 0.04% 36
2025
Q4 		$76.9K Buy
+5,000
New +$105K 0.05% 25
2025
Q3 		– Sell
-3,000
Closed -$113K – 36
2025
Q2 		$113K Buy
+3,000
New +$86.9K 0.03% 17

Other funds holding NRSN

UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
IAA
Independent Advisor Alliance Charlotte, North Carolina $4.27B AUM 45.92% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $34.3B AUM 27.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return

Yorkville Advisors Global's NRSN Position: Q2 2026 in Review

Yorkville Advisors Global held its NeuroSense Therapeutics (NRSN) position steady in Q2 2026 at 3,900 shares worth $56.2K. The position accounts for 0.07% of the portfolio, ranked #34.

Yorkville Advisors Global first reported a position in NRSN in Q2 2025 and has held it in 4 quarters since. The position peaked at $113K in Q2 2025. 12 funds tracked by Wall St. Rank hold NRSN as of Q2 2026.

  • Yorkville Advisors Global held 3,900 shares of NeuroSense Therapeutics worth $56.2K as of Q2 2026.
  • Yorkville Advisors Global left its NeuroSense Therapeutics share count unchanged in Q2 2026.
  • NeuroSense Therapeutics made up 0.07% of Yorkville Advisors Global's portfolio in Q2 2026, its #34 holding.
  • Yorkville Advisors Global first reported a position in NeuroSense Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Yorkville Advisors Global's NeuroSense Therapeutics position peaked at $113K in Q2 2025.
  • 12 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q2 2026.

Based on Yorkville Advisors Global's 13F filing for Q2 2026, filed 6 Aug 2026.